QURE’s suite of solutions measure and improve clinical practice using scientifically-validated patient simulations. We provide evidence-based guidance to help healthcare organizations reduce variation in care and improve patient outcomes.
QURE's simulated patient cases provide clinical practice data and evidence of clinical utility for life science organizations to more quickly and cost effectively bring new products to market.
Patient Simulations
QURE Care Transformation
Reduces variation in clinical practice
Serially measures and delivers evidence-based feedback
Chief Medical Officer, TRC Healthcare and President, QURE
Dr. Robert Dean joined TRC Healthcare as Chief Medical Officer and President of QURE in 2023. As an accomplished physician and top executive, Dr. Dean brings his passion and expertise for improving patient care and practice operations for health systems.
Prior to joining the team, he was the Chief Medical Officer at Northern Michigan Regional Health System and Senior Vice President of Performance Management at Vizient. Dr. Dean holds a Doctorate in Osteopathy from the College of Osteopathic Medicine and Surgery, and an M.B.A. from the University of Michigan. He completed his residency in Anesthesia and Critical Care at the University of Chicago. Dr. Dean is a Diplomat of the American Board of Anesthesiology and the American Board of Osteopathic Medical Examiners.
Robert Dean
Chief Medical Officer, TRC Healthcare and President, QURE
Trever is a nationally recognized leader in healthcare strategy and has worked extensively with senior health system leaders across the country on projects ranging from demand forecasting and value-based payment structures to clinical technology assessment and cancer center development. In addition, Trever speaks frequently at national conferences on issues on of quality and value in healthcare.
Before joining QURE, Trever served as Vice President at Sg2 (now a division of MedAssets), a healthcare analytics and intelligence company. At Sg2, Trever led the firm’s Center for Clinical Technology as well as the Oncology Strategy team. Trever holds a PhD from Stanford University in Microbiology and Immunology and received his BS from Brigham Young University.
Czarlota is a practicing internist and subspecializes in nephrology. She oversees quality control of the QURE CPV product and assists in all clinical sciences-related activities.
She holds a degree in Molecular Biology and Biotechnology from the University of the Philippines, with a thesis on DNA vaccine development for dengue fever. She finished medical school at the University of Santo Tomas, graduating cum laude. She completed internal medicine residency and adult nephrology fellowship at the University of the Philippines- Philippine General Hospital. She has a solid background in hemodialysis facility quality assurance and is a visiting faculty at Aesculap Academy, a global interdisciplinary network offering medical training for physicians and allied health professionals. She is a member of the International Society of Nephrology, the Philippine Society of Nephrology, and the Philippine College of Physicians.
David is responsible for planning and executing data analyses related to QURE’s core business, as well as guiding and overseeing the overall analytics and statistical modeling projects of the analytics team.
David received his Master of Public Health from Dartmouth College in 2003, with an emphasis in quality improvement and biostatistics, and a Bachelor of Science in Electrical Engineering from the University of California, Irvine. David has over ten years of experience related to healthcare analysis and outcomes, and he has been a contributing author to over a dozen peer-reviewed articles. Prior to this, he worked in semiconductor technology at IBM, where he fulfilled several technical and information technology roles for US and international clients to enable the success of a multiple projects.
Vice President of Clinical and Life Sciences Programs
Randy E. David, MSc, PhD serves as Vice President of Clinical and Life Sciences Programs at QURE Healthcare. For over 12 years QURE Healthcare has used its proprietary provider engagement platform to rapidly measure care decisions and evaluate the clinical utility of diagnostics, contributing to the advancement of evidence-based care. As an executive scientist, Dr. David regularly collaborates with other key thought leaders within MedTech companies and large health systems, where he has developed strategic relationships, furthered population & precision health research, and driven the adoption of innovative health technologies.
Over the course of his career, Dr. David has served as a board member and advisor for private companies, as well as government entities, and the WHO. He has held numerous academic appointments, including at the University of Kansas and the UC Irvine and Wayne State University Schools of Medicine.
Randy David
Vice President of Clinical and Life Sciences Programs
Michael is recognized as a national expert in influencing physician practice patterns at scale. He has developed methods for reducing unwarranted clinical variation through the use of unblinded peer comparisons, facilitated group discussion, mobile phone messages, national claims profiles, and most recently, simulated patients. He has served as senior physician executive at Agathos, Inc, and Embold Health.
He currently leads the development of strategic relationships at QURE Healthcare. Prior roles include Chief Medical Officer at Bay Area Hospital and VP of Variation Reduction at Sutter Health, where his method of pinpointing care variation and facilitating helpful, actionable feedback won physicians’ trust and generated millions in savings.
International Urology and Nephrology (2020): Randomized Clinical Trial of a Novel Donor-Derived cfDNA Test to Detect Rejection in CPV-Simulated Renal Transplant Patients
Journal of Oncology Practice (2019): Reducing Unwarranted Oncology Care Variation Across a Clinically Integrated Network: A Collaborative Physician Engagement Strategy
American Journal of Clinical Oncology (2019): Clinical Utility of a Blood-based Protein Assay on Diagnostic Colonoscopy Referrals for Elevated-Risk Colorectal Cancer Patients in Primary Care
The Joint Commission Journal on Quality and Patient Safety (2018): A Quality Collaboration in Heart Failure and Pneumonia Inpatient Care at Novant Health
BMJ Innovations (2020): Postmortems on Diagnostic Testing Start-Ups: Reports of Commercial Success and Failures and the Case of the Zombie Life Science Company
Journal of Clinical Medicine Research (2016): Improving Clinical Practice Using a Novel Engagement Approach: Measurement, Benchmarking and Feedback, a Longitudinal Study
Global Pediatric Medicine (2015): Low Rates of Genetic Testing in Children with Developmental Delays, Intellectual Disability, and Autism Spectrum Disorders